Results 201 to 210 of about 8,117 (271)

Patients taking benralizumab, dupilumab, or mepolizumab have lower postvaccination SARS-CoV-2 immunity.

open access: yesJournal of Allergy and Clinical Immunology
M. Runnstrom   +39 more
semanticscholar   +1 more source

Biologic Therapies for Severe Asthma: Current Insights and Future Directions. [PDF]

open access: yesJ Clin Med
Faria N   +12 more
europepmc   +1 more source

Evaluation of dupilumab and benralizumab on peripheral airway resistance and reactance

open access: yesAllergy. European Journal of Allergy and Clinical Immunology
R. Chan   +3 more
semanticscholar   +1 more source

Real-World Evidence of Administration of Biologic Agents in Patients with Severe Asthma: An Analysis of the Respiratory Department of University Hospital of Patras Asthma Registry. [PDF]

open access: yesJ Clin Med
Papaioannou O   +11 more
europepmc   +1 more source

Efficacy and Safety of Benralizumab Compared with Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Patients Receiving Standard of Care Therapy: Phase 3 MANDARA Study [PDF]

open access: bronze
Michael E. Wechsler   +15 more
openalex   +1 more source

Secondary Non-Response to Biologic Treatment in Patients with Severe Asthma. [PDF]

open access: yesJ Asthma Allergy
Mobayed H   +5 more
europepmc   +1 more source

Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease. [PDF]

open access: yesPulm Ther
Toumpanakis D   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy